Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
The watch is expected to fetch up to £30,000 when it goes under the hammer.
Leo Varadkar said that a no-deal Brexit would be a ‘nightmare scenario’.
The homes of two Sinn Fein members were attacked in west Belfast on Friday night.